Last reviewed · How we verify
Syntometrine
At a glance
| Generic name | Syntometrine |
|---|---|
| Also known as | Oxytocin methergine combination, Syntometrine 500 micrograms/5 IU Solution for Injection |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of Sublingual Misoprostol to Reduce Primary Postpartum Haemorrhage After Vaginal Delivery (PHASE4)
- Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section (PHASE4)
- A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section (NA)
- Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean (PHASE4)
- Intramuscular Oxytocics: A Randomised Control Trial (PHASE3)
- Carbetocin Versus Syntometrine for the Third Stage of Labour (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Syntometrine CI brief — competitive landscape report
- Syntometrine updates RSS · CI watch RSS
- Cairo University portfolio CI